Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from SSY Group ( (HK:2005) ).
SSY Group Limited is a Hong Kong-based pharmaceutical group active in China, specializing in the development and manufacture of bulk drugs and related preparations. The company targets major chronic and inflammatory conditions, aiming to deepen its presence in the domestic market for advanced, specialty therapies.
The Group announced that its Upadacitinib, a JAK-1 inhibitor used to treat rheumatoid arthritis, Crohn’s disease, atopic dermatitis and several other autoimmune and inflammatory disorders, has received registration approval from China’s National Medical Products Administration as a bulk drug for market preparations. This marks the third such approval granted to a PRC entity and is expected to enhance SSY’s product portfolio in immunology, potentially improving its competitive standing and opening additional revenue opportunities in China’s fast-growing market for targeted autoimmune treatments.
The most recent analyst rating on (HK:2005) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited is a pharmaceutical company based in Hong Kong, operating through subsidiaries in China. The Group focuses on the research, development and production of bulk drugs and preparations, targeting important therapeutic areas in the domestic healthcare market. Its portfolio includes treatments for autoimmune and inflammatory diseases, positioning the company within China’s growing market for advanced specialty pharmaceuticals.
The company leverages regulatory approvals from Chinese health authorities to expand its product offerings and strengthen its competitive position. By obtaining registrations for key active pharmaceutical ingredients, SSY seeks to supply both its own finished dosage products and potentially other manufacturers, supporting growth in high-value, patented or differentiated therapies.
Average Trading Volume: 8,260,550
Technical Sentiment Signal: Sell
Current Market Cap: HK$7.08B
For detailed information about 2005 stock, go to TipRanks’ Stock Analysis page.